Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors

British Journal of Pharmacology

Volumn 123, Issue 6, 1998, Pages 1230-1236

  Tirassa, Paola ^a,b   Stenfors, Carina ^b   Lundeberg, Thomas ^b   Aloe, Luigi ^a  

^a CNR   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Atropine; Brain; CCK(A); CCK(B); CCK 8 receptors; Cholecystokinin 8 (CCK 8); Hippocampus; Hypothalamus; Nerve growth factor (NGF); Pituitary

Indexed keywords

ATROPINE; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; BRAIN CORTEX; CELL DAMAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HIPPOCAMPUS; HYPOPHYSIS; HYPOTHALAMUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VAGUS NERVE;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; NERVE GROWTH FACTORS; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; SINCALIDE;

EID: 0031886272     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701718     Document Type: Article

References (55)

1. ALOE, L. (1987). Intracerebral pre-treatment with nerve growth factor prevents irreversible brain lesions in neonatal rats injected with ibotenic acid. Biotechnology, 5, 1085-1086.
2. ALOE, L. (1989). Adrenalectomy decreases nerve growth factor levels in young-adult rat hippocampus. Proc. Nat. Acad. Sci. U.S.A., 86, 5636-5640.
3. BARBANY, G. & PERSSON, H. (1992). Regulation of neurotrophin mRNA expression in the rab brain by glucocorticoids. Eur. J. Neurosci., 4, 396-403.
4. BEINFELD, M.C., MEYER, D.K., ESKAY, R.L., JENSEN, R.T. & BROWNSTEIN, M.J. (1981). The distribution of cholecystokinin in nervous system of the rat as determined by radioimmunoassay. Brain Res., 212, 51-57.
5. BLOCH, G.J., BABCOCK, A.M., GORSKI, R.A. & MICEVYCH, P.E. (1987). Cholecystokinin stimulates and inhibits lordosis behaviour in female rats. Physiol. Behav., 39, 217-224.
6. BODEN, P. & HILL, R.G. (1988). Effects of cholecystokynin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br. J. Pharmacol., 94, 246-252.
7. BRACCI-LAUDIERO, L., ALOE, L., LEVI-MONATLCINI, R., BUTTINELLI, C., SCHILTER, D., GILLESSEN, S. & OTTEN, U. (1992). Multiple sclerosis patients express increased levels of b-nerve growth factor in cerebrospinal fluid. Neurosci. Lett., 147, 9-12.
8. CHENG, B., MCMAHON, G.M. & MATTSON, M.P. (1993). Modulation of calcium current, intracellular calcium levels and cell survival by glucose deprivation and growth factors in hippocampal neurones. Brain Res., 607, 275-285.
9. CORP, E.S., MCQUADE, J., MORAN, T.H. & SMITH, G.P. (1993). Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res., 623, 161-166.
10. DAVIS, T.P. & KONINGS, P.N.M. (1993). Peptidase in the CNS: formation of biologically active, receptor-specific peptide fragment. Crit. Rev. Neurobiol., 7, 163-174.
11. DAY, H.E.W., MCKNIGHT, A.T., POAT, J.A. & HUGHES, J. (1994). Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology, 33, 719-727.
12. DOCKRAY, G.J. (1976). Immunochemical evidence for cholecystokynin-like peptides in brain. Nature, 264, 568-570.
13. DODD, J. & KELLY, J.S. (1981). The action of cholecystokynin and related peptides on pyramidal neurons of mammalian hippocampus. Brain Res., 205, 337-350.
14. EBENDAL, T. (1992). Function and evolution in the NGF family and its receptors. J. Neurosci., 32, 461-470.
15. EIDE, F.F., LOWESTEIN, D.H. & REICHARDT, L.F. (1993). Neurotrophins and their receptors-Current concepts and implications for neurologial disease. Exp. Neurol., 121, 200-214.
16. FRICKER, J. (1997). From mechanisms to drugs in Alzheimer's disease. Lancet, 349, 480.
17. GLOWINSKI, J. & IVERSEN, L.L. (1965). Regional studies of catecholamines in the rat brain: The disposition of (3H) dopa in various regions of the brain. J. Neurochem., 13, 655-669.
18. HARBAUGH, R.E. (1989). Novel CNS-direct drug delivery system in Alzheimer's disease and other neurological disorders. Neurobiol. Aging, 10, 623-629.
19. HARRO, J., VASAR, E. & BRADWEJN, J. (1993). Cholecystokinin in animal and human research of anxiety. Trends Pharmacol. Sci., 14, 244-257.
20. HEFTI, F. (1986). Nerve growth factor (NGF) promoters survival of septal cholinergic neurons after fimbrial transection. J. Neuro sci., 6, 2155-2162.
21. HEFTI, F. & SHNEIDER, L.S. (1989). Rationale for a planned clinical trials with nerve growth factor in Alzheimer's disease. Psychiatr. Dev., 4, 297-315.
22. HICKS, T.P., ALBUS, K., KANEKO, T. & BAUMFALK, U. (1993). Examination of the effects of cholecystokynin 26-33 and neuropeptides Y a response of visual cortical neurons of the cat. Neuroscience, 52, 263-279.
23. HILL, D.R., CAMPBELL, N.J., SHAW, T.W. & WOODRUFF, G.N. (1987). Autoradiographic localization and biochemical characterization of peropheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J. Neurosci., 7, 2967-2976.
24. HOLTZMAN, D.M., SHELDON, R.A., JAFFE, W., CHENG, Y. & FERRIERO, D.M. (1996). Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol., 39, 114-122.
25. KAMILARIS, T.C., JOHNSON, E.O., CALOGERO, A.E., KALOGERAS, K.T., BERNARDINI, R., CHROUSOS, G.P. & GOLD. P.W. (1992). Cholecystokinin-octapeptide stimulates hypothalamic-pituitary-adrenal function in rats: role of corticotropin-releasing factor. Endocrinology, 130, 1764-1774.
26. KATOH-SEMBA, R., SEMBA, R., KATO, H., UENO, M., ARAKAWA, Y. & KATO, K. (1994). Regulation by androgen of levels of the β-subunit of nerve growth factor and its mRNA in selected regions of the mouse brain. J. Neurochem., 62, 2141-2147.
27. KEWITZ, H., ROST, K.L., PLEUL, O. & HANDKE, A. (1990). Dose-related effects of nerve growth factor (NGF) on choline acetyltransferase (ChAT), acetylcholine (ACh) content and ACh turnover in the brain of newborn rats. Neurochem. Int., 17, 239-244.
28. KOLIATOS, V.E., NAUTA, H.T., CLATTERBUCK, R.E., HOLTZMAN, D.M., MOBLEY, W.C. & PRICE, D.L. (1990). Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in monkey. J. Neurosci., 10, 3801-3813.
29. KORSHING, S., AUURGER, G., HEUMANN, R., SCOTT, J. & THOENEN, H. (1985). Levels of nerve growth factor and its mRNA in the central nervous system of rat correlate with cholinergic innervation. EMBO J., 4, 1389-1393.
30. LAPCHAK, P.A. & HEFTI, F. (1992). BDNF and NGF treatment in lesioned rats: effects on cholinergic function and weight gain. Neuro Report, 3, 405-408.
31. LEVI-MONTALCINI, R. (1987). The nerve growth factor: Thirty-five years later. Science, 237, 1154-1162.
32. LINDE, A., UVNAS-MOBERG, K., FORSBERG, G., BEDNAR, I. & SODERSTEIN, P. (1989). Plasma concentration of cholecystokinin octapeptide and food intake in male rats treated with cholecystokinin octapeptide. J. Neuroendocrinol., 121, 59-65.
33. LINDHOLM, D., CASTRÉN, E., HENGERER, B., ZAFRA, F., BERNINGER, B. & THOENEN, H. (1992). Differential regulation of nerve growth factor (NGF) synthesis in neurons and astrocytes by glucocorticoid hormones. Eur. J. Neurosci., 4, 404-410.
34. MCCANN, M.J., VERBALIS, J.G. & STRICKER, E.M. (1988). Capsaicin pretreatment attenuates multiple responses to cholecystokinin in rats. J. Autonom. Nerv. Syst., 23, 256 272.
35. MERCER, J.G. & LAWRENCE, C.B. (1992). Selectivity of cholecystokinin (CCK) receptor antagonist. MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci. Lett., 137, 229-231.
36. MORAN, T.H., NORGREN, R., CROSBY, R.J. & MCHUGH, P.R. (1990). Central and peripheral vagal transport of cholecystokinin binding sites occurs in afferent fibres. Brain Res., 526, 95-102.
37. MORAN, T.H. & SCHWARTZ, G. (1994). Neurobiology of cholecystokinin. Crit. Rev. Neurobiol., 9, 1 28.
38. OLDENDORF, W.F. (1981). Blood-brain barrier permeability to peptides: pitfalls in measurement. Peptides, 2, 109-111.
39. OLSON, L., NORDBREG, A., VON HOLST, H., BACKMAN. L., EBENDAL, T., ALAFUZOFF, I., AMBERLA, K., HARTVIG, P., HERLITZ, A., LILJA, A., LUNDQVIST, H., LANGSTROM, B., MEYERSON, B., PERSSON, A., VIITANEN, M., WINBLAND, B. & SEIGER, A. (1992). Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural. Transm., 4, 79-95.
40. PAGE, N., GOURCH, A., OROSCO, M., COMOY, E., BOHUON, C., RODRIGUEZ, M., MARTINEZ, J., JACQUOT, C. & COHEN, Y. (1990). Changes in brain neuropeptide Y induced by cholecystokinin peptides. Neuropeptides, 17, 141-145.
41. SAFFRAN, B.N. (1992). Should intracerebroventricular nerve growth factor be used to treat Alzheimer's disease. Persp. Biol. Med., 35, 471 486.
42. SALORIO, C.F., HAMMOND, P.B., SCHWARTZ, G.J., MCHUGH, P.R. & MORAN, T.H. (1994). Age-dependent effects of CCK and devazepide in male and female rats. Physiol. Behav., 56, 645-648.
43. SAPOLSKY, R. (1992). Does glucocorticoid concentration rise with age in the rats? Neurobiol. Aging, 13, 171-176.
44. SCOTT, S.A. & CRUTCHER, K.A. (1994). Nerve Growth Factor and Alzheimer's disease. Rev. Neurosci., 5, 179-211.
45. SHINEGO, T., MIMA, T., TAKAKURA, K., GRAHAM, D., KATO, G., HASHIMOTO, Y. & FURUKAWA, S. (1991). Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J. Neurosci., 11, 2914-2919.
46. SPILLANTINI, M.G., ALOE, L., ALLEVA, E., DE SIMONE, R., GOEDERT, M. & LEVI-MONTALCINI, R. (1989). Nerve growth factor mRNA and protein increase in a mouse model of aggression. Proc. Nat. Acad. Sci. U.S.A., 86, 8555-8559.
47. THOENEN, H., BANDTLOW, C. & HEUMAN, R. (1987). The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev. Physiol. Biochem. Pharmacol., 109, 145-178.
48. TIRASSA, P., THIBLIN, I., AGREN, G., VIGNETI, E., ALOE, L. & STENFORS, C. (1997). High-dose Anabolic Androgenic Steroids modulate concentrations of Nerve growth factor and expression of its low affinity receptors (p75-NGFr) in male rat brain. J. Neurosci. Res., 47, 198-207.
49. VERBALIS, J.G., MCCANN, M.J., MCHALE, C.M. & STRICKER, E.M. (1986). Oxytocin secretion in response to cholecystokinin and food: differentiation of nausea from satiety. Science, 232, 1417-1419.
50. WANK, S.A., PISEGNA, J.R. & WEERTH, A.D. (1992). Brain gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc. Nat. Acad. Sci. U.S.A., 89, 8691-8695.
51. WEATHERFORD, S.C., CHIRUZZO, F.Y. & LAUGHTON, W.B. (1992). Satiety induced by endogenous exogenous cholecystokinin is mediated by CCK-A receptors in mice. Am. J. Physiol., 262, R574-R578.
52. WETTSTEIN, J.G., BUÉNO, L. & JUNIEN, J.L. (1994). CCK antagonists: pharmacology and therapeutic interest. Pharmacol. Ther., 62, 267-282.
53. WESKAMP, G. & OTTEN, U. (1987). An enzyme-linked immunoassay for nerve growth factort (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and peripheral tissues. J. Neurochem., 48, 1779-1786.
54. 3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res., 28, 110-114.
55. YUNSHAO, H., ZHIBIN, Y. & YICI, C. (1991). Effect of nerve growth factor on the lesioned septohippocampal cholinergic system of aged rats. Brain Res., 552, 159-163.